The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, relays the most intriguing research presentations at ASCO GU 2017.
Published: 24 February 2017
Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices
Dr. Gordan, Florida Cancer Specialists and Research Institute, describes his concerns with PBMs as they affect community oncology practices
Skip Burris, MD, offers his opinion on liquid biopsies as the new standard of care
Dr. Burris, President, Clinical Operations, Sarah Cannon, considers liquid biopsies and their role in cancer care
Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM
Dr. Patton, Chief Executive Officer, Tennessee Oncology, outlines the “four pillars” Tennessee Oncology has adopted as a result of participation ...
Lucio Gordan, MD, considers how 340B is impacting physicians and practices
Dr. Gordan, Florida Cancer Specialists and Research Institute, discusses how 340B has impacted the physicians and practices in his geography
Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network
Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, describes how community oncologists can get their patients involved in the COA Patient ...
Jeff Patton, MD, reflects on how his practice manages the transition to value-based care
Dr. Patton, Chief Executive Officer, Tennessee Oncology, elaborates on how a large practice like Tennessee Oncology, with the associated financial ...
Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference
Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, shares an example of how patients and the COA Patient Advocacy Network can ...
Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot
Dr. Patt, MPH, MBA, Vice President, Texas Oncology, lists the ways community oncology contributes to the Cancer Moonshot
Ted Okon describes how PBMs affect oncologists and cancer patients
Ted Okon, Executive Director, Community Oncology Alliance, outlines the impact PBMs have on oncologists and cancer patients
Robert Baird Jr. reflects on how his practice has changed as a result of OCM
Robert Baird Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network, shares a few of the most significant changes ...
Robert Baird Jr. on forging beneficial relationships with other cancer stakeholders
Robert Baird Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network, elaborates on how his practice has been forging ...
Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice
Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, shares how OCM ...
Lalan Wilfong, MD, shares lessons from his experience participating in OCM
Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, explains what practices ...
Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream
Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, comments on how clinical trials are able to help physicians take ...
Jeff Patton, MD, shares how clinical pathways help with value-based efforts
Dr. Patton, Chief Executive Officer, Tennessee Oncology, discusses how clinical pathways are helping with value-based efforts at Tennessee Oncology
Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM
Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, offers recommendations for community oncologists when thinking about ...
Bruce Feinberg, DO, comments on site of care and its impact on cancer economics
Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, offers his opinion on site of care and ...
Bruce Feinberg, DO, shares his special interest in value-based care
Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses his current area of interest in the ...
Ted Okon lists key takeaways from the 2017 COA meeting
Ted Okon, Executive Director, Community Oncology Alliance, provides highlights from the COA 2017 Community Oncology Conference
Debra Patt, MD, considers how community oncology contributes to clinical research advancement
Dr. Patt, MPH, MBA, Vice President, Texas Oncology, on how community oncology has contributed and advanced clinical research
Lalan Wilfong, MD, provides opinion on how OCM is changing his practice
Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, reveals how OCM ...
Debra Patt, MD, shares how community oncology has contributed to advances in population health
Dr. Patt, MPH, MBA, Vice President, Texas Oncology, reveals how community oncology has contributed to advances in population health
Debra Patt, MD, on technological advances in cancer care and community oncology
Dr. Patt, MPH, MBA, Vice President, Texas Oncology, discusses how technological advances in cancer care have been advanced by community ...
Ben Jones gives advice to practices interested in advocating for community oncology
Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, addresses health care provides and practices that want ...
Skip Burris, MD, shares how clinical pathways impact prescribing decisions
Dr. Burris, President, Clinical Operations, Sarah Cannon, offers insight into how clinical pathways impact prescribing decisions
Skip Burris, MD, discusses the importance of oral oncolytics in today’s market place
Dr. Burris, President, Clinical Operations, Sarah Cannon, considers the role of oral oncolytics in the treatment of cancer patients
Patrick Cobb, MD, describes moving to an outpatient setting and the impact on cancer care
Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, explains how moving to a hospital outpatient setting has changed the ...
Bobbi Buell on the implications of mistakes in coding
Bobbi Buell, Code Mistress, onPoint Oncology, elaborates on the implications of mistakes in coding
Ben Jones on the hot policy topics impacting the delivery of quality cancer care
Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, offers his thoughts on the hot policy topics ...
Ben Jones shares what McKesson Specialty Health is doing to help community oncologists thrive
Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, details what McKesson Specialty Health is doing to ...
Edward Li on the status of the biosimilars regulatory pathway
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses the status of the biosimilars ...
Bruce Feinberg, DO, describes how Cardinal Health is changing the world of oncology
Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, sheds light on some of the ways Cardinal ...
Skip Burris, MD, on the impact of OCM on large community practices
Dr. Burris, President, Clinical Operations, Sarah Cannon, comments on the impact of OCM on large community practices and, specifically, those ...
Edward Li outlines the legal challenges surrounding biosimilars and market entry
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, describes the legal challenges surrounding biosimilars ...
Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses how pathways have impacted oncology ...
Joseph Lynch, MD, on Professional Services Agreements versus full employment with a hospital system
Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, on the advantages and disadvantages of a Professional Services Agreement ...
David Eagle, MD, evaluates what part of total oncology care spending is drug spending
Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, focuses on the amount of drug spending in total oncology ...
Edward Li provides examples of oncology targeting biosimilars that are nearing approval
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are ...
Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents
Dr. Patton, Chief Executive Officer, Tennessee Oncology, discusses the impact of OCM on the prescribing of oral cancer agents
Jeff Patton, MD, describes the relationship between oral cancer agents and practice economics
Dr. Patton, Chief Executive Officer, Tennessee Oncology, shares his thoughts on the impact of oral cancer agents on practice economics
Edward Li considers how comfortable medical oncologists and patients should be with biosimilars
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, offers his opinion on whether medical ...
Bobbi Buell offers advice to practices on how to guarantee good coding
Bobbi Buell, Code Mistress, onPoint Oncology, offers advice to practices to assure good coding
Bobby Green, MD, describes how oncologists can leverage data to better utilize claims data
Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, recommends how oncologists should leverage data to better utilize claims data
Ted Okon shares the latest news on the 340B policy
Ted Okon, Executive Director, Community Oncology Alliance, discusses the latest on the 340B policy in Washington, D.C.
Joseph Lynch, MD, on why independent community oncology practices join hospital systems
Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, comments on why independent community oncology practices join a hospital ...
Joseph Lynch, MD, describes his practice's current arrangement with St. Francis Health System
Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, shares the evolution of his practice toward the current business ...
Joseph Lynch, MD, on how community oncologists can work closer with their local hospital system
Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, discusses the business arrangements available to community oncologists who are ...
Joseph Lynch, MD, shares how moving to the hospital setting influences quality of care
Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, comments on how quality of care can change when cancer ...
Edward Li on how clinical pathways are making progress towards their original goals
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, elaborates on whether clinical pathways are ...
David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending
Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, examines the rate of oncology spending compared to the total ...
David Eagle, MD, shares how his small practice is successful in today’s oncology environment
Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, describes how his small practice manages to thrive in today’s ...
Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem
Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, details the scope of the problem with DIR fees ...
Jeff Vacirca, MD, on COA’s efforts to represent community oncologists
Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, shares with community oncologists across the country what he ...
Ray Bailey explains how he works with payers to dispense oral cancer agents to patients
Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, shares how he works with payers to make sure ...
Ray Bailey on novel adherence approaches to help patients stay on oral cancer agents
Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, elaborates on the novel approaches to adherence FCS has ...
Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists
Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, elaborates on what COA is doing to help resolve ...
Joseph Lynch, MD, evaluates how patients react to the hospital setting versus community setting
Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, describes his experience working with patients in the hospital outpatient ...
Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients
Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, lists the goals of the COA Patient Advocacy Network and how the organization ...
Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs
Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, describes the efforts of COA to address DIR fees ...
Matt Farber provides insight on the evolution of specialty pharmacies
Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, explains how specialty pharmacies are evolving to meet the unique needs ...
Matt Farber describes how specialty pharmacies differ
Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, on whether all specialty pharmacies are the same and are associated ...
Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation
Dr. Gordan, Florida Cancer Specialists and Research Institute, shares his thoughts on how practices can improve participation in clinical trials, ...
Lucio Gordan, MD, reflects on how he sees community oncology using big data
Dr. Gordan, Florida Cancer Specialists and Research Institute, on how he envisions community oncology utilizing big data
Lucio Gordan, MD, on how community oncology practices can utilize their own data
Dr. Gordan, Florida Cancer Specialists and Research Institute, debriefs community oncology practices on how to utilize their own data to ...
Matt Farber elaborates on how specialty pharmacies work with payers to help deliver cancer care
Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, explains how specialty pharmacies work with payers to help deliver cancer ...
James Hamrick, MD, on how practices can succeed in value-based care by managing unstructured data
Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, offers his recommendation for practices to manage unstructured data in order ...
James Hamrick, MD, debriefs physicians on how to be more efficient in their workflow
Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, shares his opinion on how physicians can be more efficient in ...
James Hamrick, MD, reflects on how the EMR can overcome quality reporting challenges
Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, shares how the EMR can solve quality reporting challenges and improve ...
Matt Farber explains the role of specialty pharmacy in delivering quality cancer care
Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, describes the role specialty pharmacy plays in delivering quality cancer care
William Harwin, MD, on how clinical pathways impact treatment decisions at FCS
Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, shares how clinical pathways impact treatment decisions at FCS
Brad Prechtl on the keys to success for Florida Cancer Specialists
Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, offers his opinion on the keys to success for FCS
Brad Prechtl offers his opinion on how size influences community oncology practices
Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, on whether or not size matters when it comes to ...
Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings
Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, explains the difference in cost of cancer care between the hospital ...
Skip Burris, MD, offers his opinion on molecular profiling patients
Dr. Burris, President, Clinical Operations, Sarah Cannon, on whether or not clinicians should continue to molecular profile patients with the ...
William Harwin, MD, describes the shift from fee for service to value-based care
Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, explains the transition from fee for service to value-based care ...
William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM
Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, shares how FCS has evolved since participating in OCM
Bobbi Buell explains how practices can avoid the most common mistakes in billing
Bobbi Buell, Code Mistress, onPoint Oncology, shares the most common mistakes in billing, and how practices can overcome these mistakes
Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS
Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, provides insight into how participation in OCM impacts the ...
William Harwin, MD, on working with local payers to deliver quality care
Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, elaborates on how FCS is working with local payers to ...
David Eagle, MD, compares small, community oncology practices with large practices and hospitals
Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, explains how operating in a small community oncology practice differs ...
Skip Burris, MD, offers his opinion on searching for rare mutations
Dr. Burris, President, Clinical Operations, Sarah Cannon, on whether or not it is worth the time and expense to search ...
William Harwin, MD, explains how he manages the quality measures required for OCM
Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, offers insight into how FCS aggregate all the quality measures ...
Barbara McAneny, MD, discusses how the AMA is helping physicians working in all practice settings
Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses what the AMA is doing to help all physicians ...
Barbara McAneny, MD, on what she would like to accomplish if she became president of the AMA
Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, on what she would like to accomplish if she became ...
Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point
Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, shares her concerns with the way OCM is progressing at ...
Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM
Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses 1 sided and 2 sided risk associated with participation ...
Brad Prechtl explains how “shared savings” works between FCS and a local payer
Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, elaborates on how “shared savings” works between Florida Cancer Specialists ...
Barbara McAneny, MD, explains how the AMA and community oncology should interact
Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, explains how the AMA and community oncology should interact
Bobby Green, MD, explains how he defines big data
Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, explains how he defines big data
Bobby Green, MD, on how oncologists can leverage data to understand real quality care
Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, on how oncologists can leverage data to understand real quality care
Ricky Newton describes the paper COA is releasing on patient experiences with PBMs
Ricky Newton, CPA, Director of Financial Services & Operations, COA, describes the paper COA is releasing at this year’s meeting ...
Ricky Newton provides an example of how a PBM is impacting cancer patient care
Ricky Newton, CPA, Director of Financial Services & Operations, COA, provides an example of how a PBM is impacting cancer ...
Ricky Newton describes what happened with CVS last year and how COPA is working with CVS today
Ricky Newton, CPA, Director of Financial Services & Operations, COA, describes what happened with CVS last year and how COPA ...
Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology
Ricky Newton, CPA, Director of Financial Services & Operations, COA, tells us how COA is addressing the PBM DIR fees ...
Barbara McAneny, MD, discusses novel payer initiatives she finds interesting
Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses novel payer initiatives she finds interesting
Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, talks about if immunotherapy will be added ...
Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...
Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains what physicians need to know ...
Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE
Dr. Shore, MD, Director, Carolina Urologic Research Center, details how CHAARTED and STAMPEDE influenced his treatment of metastatic hormone sensitive ...
Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses intriguing data and presentations from ASCO GU.
Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, gives information ...
David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, gives his views on which specific drugs have ...
Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on how ...
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains how the treatment of advanced prostate cancer ...
Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, gives her perspective on the proper way ...
Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer
Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate cancer has ...
Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.
Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, relays the ...
Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, shares his thoughts on how to integrate multiple ...
Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, briefly relays the data and conclusions from ...
Ulka N. Vaishampayan, MD, on challenges facing patients and providers
Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, describes the biggest challenges facing patients and providers in the diagnosis ...
Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...
Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session
Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, discusses the results of his ASCO GU poster session.
Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment
Dr. Shore, MD, Director, Carolina Urologic Research Center, describes where chemotherapy fits into treatment for prostate cancer.
Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses treatment trends in urology for 2017 and beyond.
Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms
Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, provides insight into how immunotherapies are being integrated into renal cell ...
Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, provides her opinion on how a commercial ...
David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, explains his views on why some bladder cancer ...
Freddie C. Hamdy, MD, informs us on the ProtecT study top line results
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, relays the top line results for the ...
Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, provides his ...
Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains which metastatic castration-resistant prostate cancer patients, are ...
Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center on how CHAARTED and STAMPEDE impacted her ...
Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment
Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on how immunotherapies are being integrated into renal cell carcinoma ...
Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...
Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains how genomics are helping physicians ...
Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer
Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, discusses what physicians ...
Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients
Dr. Shore, MD, Director, Carolina Urologic Research Center, on which metastatic castration-resistant prostate cancer patients should receive chemotherapy.
Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, explains the impact his data, as presented in “General ...
Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy
Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, explains the types of metastatic renal cell carcinoma patients that should ...
Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, discusses the ...
David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, opines on whether non-invasive imaging is ready for ...
Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, discusses how the surgery, radiation, and active ...
Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, explains how ...
Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, weighs in on if genetic testing for BRCA1 ...
Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, on the fit of chemotherapy for prostate ...
Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients
Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on the optimistic view of using immunotherapies to treat renal ...
Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...
Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, provides his ...
David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the ...
Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his view on how side effects ...
Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, weighs in ...
Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, discusses how CHAARTED and STAMPEDE influences his treatment ...
David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the ...
Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his thoughts on the most exciting ...
Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers feedback on if immunotherapy will be added ...
Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, describes the ...
Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, describes how genomics are changing the ...
Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017
Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, reveals highlights from ...
Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017
Dr. Holzbeierlein, Associate Professor of Urology, University of Kansas Hospital, describes the data and conclusions he presented in “General Session ...
Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer
Dr. Shore, MD, Director, Carolina Urologic Research Center, offers his opinion on whether or not BRCA1 and BRCA2 genetic testing ...
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test
Nicholas J. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on the impact a commercial AR-V7 test ...
Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test
Dr. Shore, MD, Director, Carolina Urologic Research Center, explains how an AR-V7 commercial test will affect initial and subsequent choice ...
Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology
Dr. Saunders, Chief Executive Officer, Integra Connect, explains how the movement towards value-based care is driving technology innovation in oncology.
Charles Saunders, MD, considers EHR providers in an era of value-based care
Dr. Saunders, Chief Executive Officer, Integra Connect, offers his opinion on what EHR providers have missed in terms of supporting ...
Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment
Dr. Saunders, Chief Executive Officer, Integra Connect, explains the kind of operational transformation that will be required of oncologists to ...
Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, weighs in ...
Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017
Dr. Vaishampayan, Department of Oncology, Karmanos Cancer Institute, discusses the most intriguing research presented at ASCO GU.
David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses the impact genomics have in the way ...
Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, offers key takeaways and highlights from ...
Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications
Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, offers thoughts on ...
Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on where chemotherapy fits into treatment for prostate cancer
David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer
David J. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, relays the importance of genomics to help ...
Freddie C. Hamdy, MD, on how the design of the ProtecT study works
Dr. Hamdy, Head of the Nuffield Department of Surgery, University of Oxford, explains how the ProtecT study was designed.
Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion
Dr. Den, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on which topics ...
Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy
Dr. Aparicio, Associate Professor, The University of Texas MD Anderson Cancer Center, provides insight into who the right metastatic castration-resistant ...
Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing
Dr. Lalani, Medical Oncology, Dana Farber Cancer Institute, on the most intriguing research presentations here at ASCO GU.
Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy
Dr. Jonasch, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, ...
Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions
Jonathan Hirsch, President and Founder, Syapse, on precision medicine software helping oncologists make therapeutic decisions at the point of care
Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment
Jonathan Hirsch, President and Founder, Syapse, discusses how precision medicine is being used to help improve cancer treatment
Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information
Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information
Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care
Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, explains how Flatiron analytics help practices succeed in value ...
Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists
Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, discusses how the clinical data set at Flatiron helps ...
Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate
Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, discusses how technology is helping reform the way community ...
Mike Kolodziej, MD, talks about how CMMI is changing the health care system
Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, talks about how CMMI is changing the health care ...
Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry
Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, explains the impact of the ACA on the insurance ...
Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance
Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses how practices and administrators can build higher pathway compliance
Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines
Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, explains how clinical pathways differ from clinical guidelines
Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care
Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses if clinical pathways create value in cancer care
Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer
Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, explains how clinical pathways save money when treating cancer
Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care
Maddy Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems, on how oncology practices consume patient-reported data to improve patient ...
Maddy Herzfeld, on solutions available for practices to implement better patient engagement
Maddy Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems, on potential solutions available for practices to implement better patient ...
Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement
Maddy Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems, discusses the challenges practices are facing when implementing patient engagement
Bobby Green, MD, on leveraging genomic testing into actionable data
Bobby Green, MD, Senior VP, Clinical Oncology, Flatiron Health, on leveraging genomic testing into actionable data
Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine
Bobby Green, MD, Senior VP, Clinical Oncology, Flatiron Health, discusses how Flatiron and Foundation Medicine work together to combine genomic ...
Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials
Bobby Green, MD, Senior VP, Clinical Oncology, Flatiron Health, explains if genomic data can be used to prescreen patient eligibility ...
Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care
Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, explains his vision for how GPOs must evolve in the era of value-based ...
Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings
Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, discusses best practices that a GPO can implement to help with value-based savings
Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations
Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, on how important the drug channel is compared to reduction in hospitalizations
Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings
Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, shares the highest-impact areas of focus for value-based care savings, inside and outside ...
Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists
Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, on whether the ACA changed access to care at New England ...
Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care
Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, explains how New England Cancer Specialists helps patients get access to ...
Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices
Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, on why this is a challenging time for oncology practices
Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM
Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, talks about what technology his practice adopted to participate in OCM
Steve D’Amato, R.Ph., talks about data capture and data analytics at New England Cancer Specialists
Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, talks about data capture and data analytics at New England Cancer ...
Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices
Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health, on the differences working with hospital-based cancer centers versus community oncology practices
Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model
Diana Verrilli, Vice President/General Manager Managed Care, McKesson Specialty Health, on how claims data can be used to help practices ...
Diana Verrilli, McKesson Specialty Health, on how claims data is being used
Diana Verrilli, Vice President/General Manager Managed Care, McKesson Specialty Health, on how claims data is being used to change patterns ...
Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents
Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies, discusses how limited distribution impacts the delivery ...
Ira Klein, MD, explains how risk management changes the way we manage supply chain
Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies, explains how risk management changes the way ...
Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model
Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health, explains the challenges for oncologists and practices with the OCM model
Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care
Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health, tells us what oncologists should be thinking about today as they approach ...
Ira Klein, MD, on what the shift toward oral oncolytics means for the supply chain
Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies, on what the shift toward oral oncolytics ...
Dave Terry, Chief Executive Officer, explains why practices should participate in APMs
Dave Terry, Chief Executive Officer, Archway Health, explains why practices should participate in Alternative Payment Models
Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future
Dave Terry, Chief Executive Officer, Archway Health, shares his thoughts on Alternative Payment Models of the future
Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs
Dave Terry, Chief Executive Officer, Archway Health, on the keys to success when participating in Alternative Payment Models
Debra Patt, MD, on what tele-health brings to cancer care
Dr. Patt, Vice President, Texas Oncology, on what tele-health brings to cancer care
Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM
Dr. Bosserman, City of Hope Medical Foundation, on how a practice should decide whether to participate in MIPS or an ...
Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA
Dr. Bosserman, City of Hope Medical Foundation, explains “Pick Your Pace” as it relates to participation in MACRA
Debra Patt, MD, explains using predictive analytics to improve cancer care delivery
Dr. Patt, Vice President, Texas Oncology, explains using predictive analytics to improve cancer care delivery
Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care
Dr. Patt, Vice President, Texas Oncology, explains how decision support tools improve the quality and delivery of cancer care
James Hamrick, MD, explains how EMRs help connect patients and caregivers
Dr. Hamrick, Practicing Community Oncologist and Senior Medical Director, Flatiron Health, explains how EMRs help connect patients and caregivers
Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope
Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, on how cancer care ...
Harlan Levine, MD, on treating patients in this era of high cost cancer drugs
Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, explains what City of ...
Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment
Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, explains the requirements that must ...
Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work
Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, shares her thoughts on the ...
James Hamrick, MD, on using real world evidence to learn how to treat cancer patients
Dr. Hamrick, Practicing Community Oncologist and Senior Medical Director, Flatiron Health, on using real world evidence to learn how to ...
Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO
Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, on the philosophy for ...
Harlan Levine, MD, tells us about the continuous cycle of learning and improving at City of Hope
Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, tells us about the ...
Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment
Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, explains how an episode of ...
Lili Brillstein, M.P.H., explains the primary goal of an episode of care
Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, explains the primary goal of ...
Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017
Dr. Bosserman, City of Hope Medical Foundation, discusses the highlights of the MACRA panel at CCBS 2017
Linda Bosserman, MD, explains what MACRA means for oncologists today
Dr. Bosserman, City of Hope Medical Foundation, explains what MACRA means for oncologists today
Debra Patt, MD, explains how data systems help with patient care delivery in community oncology
Dr. Patt, Vice President, Texas Oncology, explains how data systems are helping with patient care delivery in community oncology
James Hamrick, MD, shares his thoughts on how we are evolving toward a learning health care system
Dr. Hamrick, Practicing Community Oncologist and Senior Medical Director, Flatiron Health, shares his thoughts on how we are evolving toward ...
Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses which molecular tests to order for ...
Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, explains how the 80405 study in CRC ...
Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on integrating immunotherapy into existing treatment regimens for CRC patients
Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on which molecular tests to order for a newly diagnosed ...
Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, shares his perspective on how to use both TAS-102 and ...
Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, talks about the DFCI wellness study demonstrating that CRC patients ...
John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, tells us how vaccines can be used to broaden the ...
John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how checkpoint inhibitors are being integrated into treatment of ...
John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how to integrate genetic mutations, and left sided vs ...
Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on whether resected pancreatic cancer patients should be offered adjuvant ...
Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage ...
John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, discusses which molecular tests to order when determining treatment approach ...
John L. Marshall, MD, talks about the results of the RESORCE trial
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, talks about the results of the RESORCE trial and how ...
Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how new agents being studied for advanced HCC will be integrated into ...
Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, discusses the outcomes of the RESORCE trial as presented here at ASCO GI ...
Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...
Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on reliably identifying subgroups of patients for targeted therapies in HCC
Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how checkpoint inhibitors will be incorporated into the treatment of unresectable HCC
Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on identifying subgroups of HCC patients that ...
Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...
Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...
Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on whether physicians will incorporate regorafenib into clinical practice
Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on if the RESORCE trial will change ...
Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, provides his perspective on how to use ...
Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study
Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the quality of life data from the NETTER-1 study
Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study
Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the results of the NETTER-1 study
Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102
Dr. Hochster, Associate Director, Yale Cancer Center, differentiates regorafenib from 5FU and TAS-102 from a mechanism of action perspective
Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, explains the outcomes of the randomized phase 2 study in BRAF mutated CRC ...
Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients
Dr. Hochster, Associate Director, Yale Cancer Center, on integrating immunotherapy into existing treatment regimens for GI cancer patients
Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a ...
Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, discusses if genetic profiling has changed the approach to treating CRC patients
Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, explains how new agents in advanced HCC are being integrated into treatment
Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses the outcomes of the RESORCE trial
Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses how checkpoint inhibitors be incorporated into the treatment of unresectable HCC
Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, shares his thoughts on whether physicians will incorporate regorafenib into clinical practice
Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, on identifying subgroups of patients for targeted therapies in HCC
Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, shares her thoughts on some exciting trials or drugs ...
Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, discusses some of the challenges in treating pancreatic cancer
Johanna Bendell, MD, discusses the RESORCE trial data
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, provides her expectations on how the RESORCE trial data ...
Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the Proprietary Neoantigen Identification Technology platform
Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses how new agents being studied for ...
Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains the outcomes of the RESORCE trial ...
Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, shares her thoughts on whether physicians will ...
Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted ...
Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains how checkpoint inhibitors will be incorporated ...
Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, talks about how integrating immunotherapy into existing treatment regimens for CRC ...
Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how organoids are being used for cancer biology research
Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses integrating immunotherapy into existing treatment regimens for GI cancer ...
Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, discusses the goals of the NCI-MATCH trial and the progress to ...
Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the outcomes of the randomized phase 2 study in ...
Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the phase 3 study in advanced gastric ...
Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains which molecular tests help determine treatment approach
Edith P. Mitchell, MD, on how classifications of gastric cancer subtypes are impacting treatment
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how new classifications of gastric cancer subtypes based on molecular ...
Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how the Blue Ribbon Panel may help with the Cancer ...
Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies
Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, talks about ...
Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate
Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, weighs in ...
Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective
Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, provides insight ...
Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients
Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains the ...
Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas
Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains how ...
Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides viewpoint on how physicians should sequence ...
Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on exciting news coming out of ASH ...
Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides opinion on if the word “cure” ...
Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, discusses optimism about the use of immunotherapies ...
Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on if payers are using clinical pathways in ...
Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on which ASH 2016 CLL presentations have caught ...
Alexander Perl, MD, discusses treatment options for AML patients
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, weighs in on AML treatment options in patients ...
Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, discusses patient and hematologist challenges in the prognosis, ...
Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, gives his feedback on trials looking at treatment ...
Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on which ASH AML trial results have been ...
Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on intriguing data for CLL coming out of ASH 2016
Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses the latest updates in T cell lymphomas that is being presented ...
Swaminathan Iyer, MD, discusses exciting new CLL treatment options
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, talks about exciting new treatment options for CLL
C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses the best way for physicians to manage MRD negative patients
C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, talks about which and why, multiple myeloma patients should be tested for ...
C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on the current treatment algorithm for smoldering myeloma patients
C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses his optimism around the use of of immunotherapies treatment for multiple ...
Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients
Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on the incorporation of immunotherapies into treatment algorithms ...
Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin
Dr. Prince, Professor, The University of Melbourne and Monash University, on how he expects CTCL patients to be impacted by ...
Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016
Dr. Prince, Professor, The University of Melbourne and Monash University, on ASH 2016 positive news for CTCL patients
David Miklos, MD, on developing an orphan drug for a small population of patients
Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, relays his pharmaceutical company experience in developing an ...
Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016
Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, on which clinical advances in CLL ...
Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, on big changes discovered in the ASH meetings in ...
Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the new drugs worth mentioning
Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML
Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, talks about how important drug ...
Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, discusses ...
Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...
Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...
Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains how to integrate stem cell transplantation into the treatment of ...
Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, talks about how stem cell transplant figures into the treatment algorithm ...
Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, speaks to which stem cell transplantation studies are most exciting and ...
Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients
Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, speaks ...
Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas
Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, talks ...
Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies
Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, provides ...
Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses which ASH 2016 presentations were the ...
Michael Kauffman, MD, on Selinexor regulatory and commercialization plans
Dr. Kauffman, CEO Karyopharm Therapeutics, discusses the regulatory and commercialization plans for Selinexor
Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, relays ...
Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, explains how immunotherapies are being integrated into multiple myeloma treatment algorithms
Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on personalized medicine and its impact on the treatment ...
Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on what physicians should be aware of when ...
Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, provides his thoughts on whether multiple myeloma can be cured one day
Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, explains how the CPX 351 data may impact the market and how ...
Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, on ...
Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL
Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, gives her view on exciting ...
Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses how romidepsin should be incorporated into the treatment of patients with ...
Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients
Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, talks about the outcomes in his ...
Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients
Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, speaks about the unmet medical need ...
David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients
Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, on how stem cell and bone marrow transplant ...
David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD
Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, explains the phase 2 ibrutinib study outcomes for ...
Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients
Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on her findings of the most exciting news ...
Jane Winter, MD, talks about how personalized medicine is being applied to NHL
Dr. Winter, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, weighs in on how personalized medicine is being applied ...
C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on how physicians should base treatment decisions on MRD test results for ...
C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on what he found to be the most exciting news at ASH ...
Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on how physicians should incorporate ofatumumab into the treatment of untreated CLL ...
Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, talks about how the BEAT AML master trial ...
Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on how molecular testing can be used to ...
Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, relays the end goals for the multiple ...
Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on how the multiple myeloma genome project ...
Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the role of selinexor and the STORM ...
Eunice Wang, MD, talks about the challenges in treating elderly patients with AML
Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, discusses challenges and strategies to ...
Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, talks about the advances in CLL and the ...
Edward Copelan, MD, discusses the Levine Cancer Institute Program
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, talks about his Levine Cancer Institute program
Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19
Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, discusses the results of the ZUMA-1 pivotal phase ...
Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients
Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, explains what the results of ZUMA-1 mean to ...
Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective
Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses what new targets could make ...
Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19
Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses the results of the ZUMA-1 ...
Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
Dr. Prince, Professor, The University of Melbourne and Monash University, talks about the outcomes of the ALCANZA study in CD30-expressing ...
Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016
Dr. O’Brien, Professor of Medicine, University of California, Irvine, shares her thoughts on the advancements in the treatment of leukemia ...
Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, provides insight on how elderly patients with hematological ...
Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, discusses how clinical pathways are being incorporated into ...
Michael Kauffman, MD, on how Selinexor works
Dr. Kauffman, CEO Karyopharm Therapeutics, on how Selinexor works
Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients
Dr. Kauffman, CEO Karyopharm Therapeutics, explains the clinical evidence on Selinexor that is helping relapsed, refractory multiple myeloma patients
Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he reduced the number of ...
Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH
Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in T-cell lymphomas presented at ...
Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH
Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in cutaneous lymphomas presented at ...
Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, discusses CPX 351 in older high-risk patients in AML
Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, talks about the importance of the AGIOS 221 data
Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks bout the key takeaways from ASH 2016 presentation ...
Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, discusses the latest developments in stem cell transplantation here at ASH ...
Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains the effectiveness of novel immunotherapies in the treatment of multiple ...
Susan O’Brien, MD, discusses CLL presentations at ASH 2016
Dr. O’Brien, Professor of Medicine, University of California, Irvine, discusses CLL presentations at ASH 2016
Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today
Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, shares his thoughts on the most exciting treatment options available in multiple ...
Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016
Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses venetoclax and why it stands out as one of the most ...
Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)
Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses selinexor (KPT-330) and why it stands out as one of the ...
Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor
Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, explains the importance of ...
Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her thoughts on investigational drugs in ...
Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, discusses regimen preference in mCRC 1st line ...
Skip Burris, MD, talks about how CAR-Ts work, and the trials taking place at SCRI
Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, talks about how CAR-Ts work, and the trials taking place ...
Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on how ...
Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment
Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, provides feedback on new agents being studied for advanced HCC and ...
Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about progress being made developing ...
Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center talks on how PD-L1 ...
Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the different approaches being studied to make ...
Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)
Robert Figlin, MD, Steven Spielberg Chair in Hematology-Oncology, discusses recent clinical advances, including overall survival benefit, when treating renal cell ...
Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center discusses treatment strategies because of ...
Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies
Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides insights into ...
Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patients
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center explains how PD-L1 inhibitors and other immunotherapies are being developed for the ...
Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses optimal dosage for Stivarga (regorafenib) in the 2nd ...
Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on patient ...
David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients
During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, discusses the importance ...
Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective on immunotherapy and how ...
David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients
During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center shares ...
Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond
Phil Bonomi, MD, Professor, Rush University Medical Center, talks about the evolving role of targeted agents, such as ramucirumab, in 2nd ...
Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine answers the reliability of MSI-High as a predictor of response ...
Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC
Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, on which classes and products in development look promising for the ...
Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies
Jeffrey Weber, MD, PhD, Co-Director of Melanoma Program, NYU Langone Medical Center, discusses the response rates and PFS for longer ...
Laura Chow, MD discusses incorporating checkpoint inhibitors into standard of care
Laura Chow, MD, Associate Professor, Medical Oncology, University of Washington School of Medicine, discusses incorporating checkpoint inhibitors into standard of ...
Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, talks about the progress made in selecting ...
Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the evolving development ...
Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC
Anthony El-Khoueiry, MD, Associate Professor of Clinical Medicine, Kenneth Norris Comprehensive Cancer Center, discuss products being developed for hepatocellular carcinoma ...
Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, shares his thoughts on testing ...
Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the economic versus efficacy outcomes in CALGB/SWOG ...
Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies
Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, answers whether long term response rate and PFS ...
Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3
During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...
Eunice S. Wang, MD, discusses the importance hitting the FLT3 target
Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, highlights some key data at the ASCO ...
Value Tools at ASCO 2016: Building a Framework for Prime Time (Part 3)
Value tools, i.e. the ASCO Value Framework and the NCCN Evidence Blocks, received a lot of attention at ASCO ’16. ...
Laura Chow, MD, provides the rationale for studying PD-L1 inhibitors in SCCHN
Laura Chow, MD, Associate Professor, University of Washington School of Medicine, provides the rationale for studying PD-L1 inhibitors in recurrent ...
Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker
Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, relays the importance of ...
Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies
Jeffrey Weber, MD, PhD, Co-Director of Melanoma Program, NYU Langone Medical Center, relays the long term data specific to the ...
Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy
Jeffrey Weber, MD, PhD, Co-Director of Melanoma Program, NYU Langone Medical Center, discusses the efficacy of checkpoint inhibitors and immunotherapy ...
Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results
Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, provides interpretation of the ...
Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, talks about the importance of considering performance status when selecting therapy ...
Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC
Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, comments on utilizing regorafenib (Stivarga) and trifluridine (Lonserf) in 3rd line ...
Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, discusses the importance of giving ipilimumab (Yervoy) prior to nivolumab (Opdivo) ...
Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, shares on the reliability of Microsatellite instability-High (MSI-High) as a predictor ...
Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients
Tanios Bekali-Saab, MD, Professor of Medicine, Mayo Clinic, comments on whether KRAS can be used to determine treatment approaches knowing ...
Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of ...
Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of ...
Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting
Phil Bonomi, MD, Professor, Rush University Medical Center, shares his thoughts on the potential importance of checkpoint inhibitors in the ...
Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy
Phil Bonomi, MD, Professor, Rush University Medical Center, shares his thoughts on the costs of new lung cancer therapies relative to ...
Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, discusses the role of CDK ...
Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, shares his thoughts on the ...
Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, comments on the results of ...
Mark Levis, MD, discusses significance of the Quantum-R study
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...
Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...
Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on the ...
Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on the ...
Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on why ...
Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides his thoughts on the ...
Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...
Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the concept of ...
Julie Gralow, MD, on the KRISTINE study
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comment on the KRISTINE study of preoperative ...
Julie Gralow, MD, discusses the Monarch 1 study
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comments on the Monarch 1 study of ...
Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, discusses the outcomes of the PALOMA-2 trial ...
Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients
During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine provides practical advise for ...
Julie Brahmer, MD, on the importance of overall cost of therapy
During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine discusses the importance of ...
Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC
During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine shares her perspective on ...
Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.
Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on new drugs in ...
Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment
Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on liquid biopsy as ...
Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study
Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on the PALOMA-2 randomized ...
Eunice S. Wang, MD, discusses the Quantum First Study
Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, comments on the Quantum First Study, ...
Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent
During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...
Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML
Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute talks about Crenolanib and its activity in ...
Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor
Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares why sustained inhibition may be important ...
Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important
Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares why FLT3 is important and provides ...
Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies
Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective on immunotherapy and how ...
David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients
During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine discussed with OBR ...
David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC
During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine talks about when ...
David Ettinger, MD, talks about levels of PD-L1 expression and agent selection
During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, shares his perspective ...
Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study
During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...
Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets
During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, discusses the application of ...
Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment
During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...
Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent
During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...
Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor
During the 2016 ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares why specificity ...
Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor
Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares why sustained inhibition may be important in ...
Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies
Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on immunotherapy and it may ...
Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)
Anthony El-Khoueiry, MD, Associate professor of Clinical Medicine at the Kenneth Norris Comprehensive Cancer Center discusses results of nivolumab (Opdivo) ...
Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC
Anthony El-Khoueiry, MD, Associate professor of Clinical Medicine at the Kenneth Norris Comprehensive Cancer Center, talks about the management of ...
Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years
Anthony El-Khoueiry, MD, Associate professor of Clinical Medicine at the Kenneth Norris Comprehensive Cancer Center, talks about changes in HCC ...
Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent
During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...
Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania talks about Crenolanib and its activity in ...
Alexander Perl, MD, discusses the Quantum First Study and potential implications
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, comments on the Quantum First Study, ...
Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why sustained inhibition may be important ...
Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why potency may be important in ...
Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why FLT3 is important and provides ...
Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target
Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, highlights some key data at the ASCO ...
David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC
During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center discusses ...
Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients
During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine talks about when agents ...
Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy
During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine discussed with OBR practical ...
Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC
During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine discusses the potential future ...
David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients
During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, discusses the potential ...
Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study
During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...
Mark Levis, MD, on why the FLT3 target is important in AML
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides his thoughts on why ...
Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies
Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...
Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results
During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...
David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients
During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, provides practical advice ...
Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine, on the phase 3 CALGB/SWOG 80405 study outcomes regarding primary ...
Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine, discusses treatment changes due to primary site of tumor overall ...
Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine on if left versus right-sided primary tumor provides a predictive ...
Howard Hochster, MD on performance status importance in selecting treatment algorithms
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine weighs in on performance status importance in determining treatment algorithms ...
Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine discusses how the economic benefit seen in CALGB/SWOG 80405 compares ...
Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine on the non MSI-High immunotherapy development progress for CRC patients
Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC
Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, provides feedback on the rationale for studying PD-L1 inhibition in advanced ...
Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC
Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, discusses which late stage clinical studies could potentially impact the standard ...
Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies
Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, discusses the unique toxicities that physicians are seeing ...
Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used
Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, discusses if there is a stopping point where, ...
Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy
Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, agrees there will be broad use of immunotherapies ...
Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)
During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...
Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective progress being made toward selecting the right patient ...
Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on immunotherapy in CRC and what clinicians can ...
Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC
Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, provides her perspective on how the Institute for ...
Tanios Bekaii-Saab, MD, on outcomes of CALGB/SWOG 80405 regarding primary site of tumor
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of ...
Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, explains how to integrate Stivarga (regorafenib) and Lonserf (trifluridine) ...
Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses the importance of giving Yervoy (ipilimumab) prior to ...
Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on the reliability of MSI-High as a predictor of ...
Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses phase 3 CALGB/SWOG 80405 study outcomes regarding primary ...
Philip Philip, MD on what is impressing him at ASCO 2016 in CRC
Philip Phillip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute on what is impressing him at ASCO 2016 in ...
Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC
Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, discusses the main toxicity concerns and how to manage with the ...
Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents
Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center relays the pipeline’s ...
Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016
Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center on the results ...
Laura Chow, MD tells us about products in development for SCCHN
Laura Chow, MD, Associate Professor, University of Washington School of Medicine, provides some insight into the products in the pipeline ...
Laura Chow, MD discusses cross trial comparisons with Keytruda and Opdivo in head and neck cancers
Laura Chow, MD, Associate Professor, Medical Oncology, University of Washington School of Medicine, discusses cross trial comparisons with Keytruda (pembrolizumab) ...
Laura Chow, MD discusses the role of PD-L1 testing in SCCHN
Laura Chow, MD, Associate Professor, University of Washington School of Medicine, discusses the role of PD-L1 testing in squamous cell ...
Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma
Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, explains the long term ...
Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses the top PD-1 or PD-L1 inhibitor treatment ...
Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, provides the big picture ...
Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy
Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center on how toxicities factor into decision making for later ...
Barbara Burtness, MD talks about new patient treatment insights based on the Keynote-055 study
Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine on if response rates by anatomic site in the ...
Barbara Burtness, MD explains if the Keynote-012 study confirms the benefit seen with Keytruda
Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine explains if updated data confirms the Keynote-012 study durable ...
David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients
David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses the KEYNOTE-O10 study of ...
David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy
During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center discussed ...
David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients
During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses ...
Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study
Laura Chow, MD, Associate Professor, University of Washington School of Medicine, interprets the overall survival benefit with Opdivo (nivolumab) in ...
Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about whether the phase 3 ...
Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016
Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides his perspective ...
Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center relays the outcomes of the ...
Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm
Robert Figlin, MD, Steven Spielberg Chair in Hematology-Oncology, discusses the challenge in treating 2nd line kidney cancer and how he ...
Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, explains how cabozantinib can fit into renal cell carcinoma (RCC) treatment ...
Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, provides a clinical study update on the use of nivolumab (Opdivo®) ...
Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center on reaffirmation of efficacy ...
Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on the ...